BioSpace News Archive

Flamingo Therapeutics., a biotechnology company pioneering RNA-targeting therapies in oncology, announced that Mike Garrett, Chief Executive Officer, will present at the BioCapital Europe 2022 meeting on March 10th, 2022 at 5pm CET/11am ET.

Innovation Pharmaceuticals today reported findings from data review of the Company’s Brilacidin Phase 2 COVID-19 study and compassionate use of Brilacidin in critically-ill COVID-19 patients.

NeuBase Therapeutics, Inc. announced today that company management will participate in a fireside chat and will be available for one-on-one meetings at Oppenheimer’s 32nd Annual Healthcare Conference being held virtually March 15 – 17, 2022.

Longeveron Inc. today announced that the Company will release its fourth quarter and year-end 2021 financial results on Friday, March 11, 2022 before the open of U.S. financial markets.

aTyr Pharma, Inc. today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update after the market close on Monday, March 14, 2022.

Baudax Bio, Inc. announced that the Company received a letter on March 3, 2022 from The Nasdaq Stock Market noting the Company has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the Company to maintain a minimum closing bid price of $1.00 per share.

Immix Biopharma, Inc. today announced the IMMX Milestone Day Event, to be held on April 5, 2022.

Brooklyn ImmunoTherapeutics, Inc. today announced that it has entered into a definitive agreement to sell securities in a private placement with a leading healthcare investor.

Hepion Pharmaceuticals, Inc. announced today that its CMO, Dr. Todd Hobbs, will present at the Q1 Investor Summit Conference on Wednesday, March 9, 2022 at 1:15 p.m. Eastern Time.

Alterity Therapeutics today announced that David Stamler , M.D., Chief Executive Officer will present a company update and participate in investor meetings at the 34th Annual Roth Conference.